Ballentine Partners LLC Invests $301,000 in Encompass Health Corporation $EHC

Ballentine Partners LLC acquired a new position in Encompass Health Corporation (NYSE:EHC) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,454 shares of the company’s stock, valued at approximately $301,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. WPG Advisers LLC bought a new stake in Encompass Health during the 1st quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Encompass Health by 749.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company’s stock valued at $42,000 after buying an additional 367 shares in the last quarter. Arlington Trust Co LLC raised its position in shares of Encompass Health by 22.9% during the first quarter. Arlington Trust Co LLC now owns 671 shares of the company’s stock valued at $68,000 after buying an additional 125 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Encompass Health by 19.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 720 shares of the company’s stock worth $73,000 after buying an additional 115 shares in the last quarter. Finally, SVB Wealth LLC bought a new position in shares of Encompass Health during the first quarter worth $84,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EHC has been the topic of several research analyst reports. Stephens upgraded shares of Encompass Health from an “overweight” rating to a “strong-buy” rating and set a $135.00 price target on the stock in a research note on Thursday, June 5th. UBS Group boosted their target price on Encompass Health from $130.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Wall Street Zen cut Encompass Health from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Truist Financial lifted their price objective on Encompass Health from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Finally, Bank of America increased their target price on Encompass Health from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $138.43.

Insider Activity

In related news, EVP Patrick William Tuer sold 1,020 shares of the firm’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the sale, the executive vice president directly owned 18,846 shares of the company’s stock, valued at approximately $2,329,177.14. This trade represents a 5.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.10% of the company’s stock.

Encompass Health Stock Up 0.9%

Shares of EHC opened at $126.78 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 52-week low of $87.85 and a 52-week high of $127.86. The company has a market cap of $12.77 billion, a PE ratio of 24.81, a P/E/G ratio of 2.22 and a beta of 0.92. The business has a fifty day moving average of $119.60 and a 200 day moving average of $114.84.

Encompass Health (NYSE:EHC) last released its earnings results on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.20. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter last year, the business earned $1.11 EPS. The business’s revenue was up 12.0% on a year-over-year basis. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. On average, sell-side analysts expect that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Wednesday, October 1st will be issued a $0.19 dividend. The ex-dividend date is Wednesday, October 1st. This is a positive change from Encompass Health’s previous quarterly dividend of $0.17. This represents a $0.76 annualized dividend and a dividend yield of 0.6%. Encompass Health’s dividend payout ratio (DPR) is currently 13.31%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.